As of today (2022-05-28), Guardant Health's share price is $43.00.
Guardant Health's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2022 was $-3.05. Hence, Guardant Health's Price-to-Free-Cash-Flow Ratio for today is .
The historical rank and industry rank for Guardant Health's Price-to-Free-Cash-Flow or its related term are showing as below:
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 2.60% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was -25.10% per year.
During the past 6 years, Guardant Health's highest 3-Year average Free Cash Flow per Share Growth Rate was 2.60% per year. The lowest was -12.10% per year. And the median was -11.50% per year.
Guardant Health Price-to-Free-Cash-Flow Historical Data
The historical data trend for Guardant Health's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Guardant Health Annual Data
Trend
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Price-to-Free-Cash-Flow
-
-
-
-
-
Guardant Health Quarterly Data
Dec16
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Price-to-Free-Cash-Flow
-
-
-
-
-
Competitive Comparison
For the Diagnostics & Research subindustry, Guardant Health's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guardant Health Price-to-Free-Cash-Flow Distribution
For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Guardant Health's Price-to-Free-Cash-Flow falls into.
Guardant Health Price-to-Free-Cash-Flow Calculation
Guardant Health's Price-to-Free-Cash-Flow ratio for today is calculated as
Guardant Health's Share Price of today is $43.00.
Guardant Health's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.05.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Guardant Health (NAS:GH) Price-to-Free-Cash-Flow Explanation
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Guardant Health Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of Guardant Health's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company's pipeline includes Guardant Reveal (formerly Lunar-1), for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
4.48(11.63%) Volume: 1,303,995 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:GH has been successfully added to your 
